

PATENT  
IN THE UNITED STATES PATENT & TRADEMARK OFFICE

Applicant: L. Alani, et al.

Serial No.: 09/576,097

Filed: May 22, 2000

For: IMPROVED PHARMACEUTICAL  
FORMULATIONS

Examiner: D. Lukton

Group Art Unit: 1653

Docket No.: 6499.US.02

Date: June 27, 2001



Certificate of Mailing (37 C.F.R. 1.8(a))

I hereby certify that this paper (along with any paper referred to as being attached or enclosed) is being deposited with the United States Postal Service on the date shown below with sufficient postage as first class mail in an envelope addressed to the:

Commissioner for Patents  
Washington, D. C. 20231, on:

Date of Deposit: June 27, 2001

Wanda E. Smith Date

Handwritten initials and date: #7, KO, 9-8-01

Wanda C. Smith 6/27/01

**RESPONSE**

Commissioner for Patents  
Washington, D.C. 20231

Dear Sir:

This is a response to the Restriction Requirement dated April 17, 2001, the period for response to which has been extended from May 17, 2001 to July 17, 2001. Applicants also provide herewith a Supplemental Information Disclosure Statement.

**Response to Restriction Requirement**

In the Restriction Requirement, the Examiner requires restriction of the claims to one of 5 restriction groups. Applicants elect the Examiner's restriction group 1 (Claims 1-11, drawn to compositions in which the inhibitor is limited to G1, and the solvent and surfactant can vary as the claims permit, along with Claims 12-19). For purposes of the Examiner's search, Applicants point out that preferred HIV protease inhibitors within the elected claims are ritonavir (see Claim 2) and a combination of ritonavir and ABT-378 (see Claim 3).

**Supplemental Information Disclosure Statement**

Applicants submit herewith a Supplemental Information Disclosure Statement and Form PTO1449. The following information is submitted pursuant to 37 C.F.R. 1.97 and 1.98 in accordance with Applicants' duty of disclosure under 37 C.F.R. 1.56. This submission is not an admission that the documents cited herein are prior art as to the invention claimed. Because this Information Disclosure Statement is submitted before the first Office Action on the merits, no fee is required.


The following references are known to Applicants:

1. J. Lipari, et al., U.S. Patent No. 6,232,333, issued May 15, 2001.
2. D. Kempf, et al., U.S. Patent No. 5,541,206, issued July 30, 1996.
3. L. Al-Razzak, et al., U.S. Patent No. 5,484,801, issued January 16, 1996.
4. L. Al-Razzak, et al. U.S. Patent No. 5,948,436, issued September 7, 1999.
5. J. Lipari, et al., International Patent Application No. WO98/22106, published May 28, 1998.
6. D. Norbeck, et al., International Patent Application No. WO97/01349, published January 16, 1997.
7. L. Al-Razzak, et al., International Patent Application No. WO95/09614, published April 13, 1995.
8. L. Al-Razzak, et al., International Patent Application No. WO95/07696, published March 23, 1995.
9. E. Rudnic, et al., International Patent Application No. WO95/25504, published September 28, 1995.
10. H. Sham, et al., International Patent Application No. WO97/21685, published June 19, 1997.

**Action Requested**

Favorable action on Claims 1-19 is respectfully requested.

Respectfully submitted,  
L. Alani, et al.



Dr. Steven R. Crowley  
Registration No. 31,604  
Agent for Applicants

Abbott Laboratories  
D-377/AP6D-2  
100 Abbott Park Road  
Abbott Park, IL. 60064-6050  
(847) 937-9516